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Summary
Wild type human full length (f.l.) tumor suppressor p53 protein binds preferentially to super-
coiled (sc) DNA in vitro both in the presence and absence of the p53 consensus sequence
(p53CON). This binding produces a ladder of retarded bands on the agarose gel. Bands
revealed by immunoblotting with antibody DO-1 corresponded to the ethidium stained retard-
ed bands. The intensity and the number of bands of p53-scDNA complex were decreased by
physiological concentrations of unchelated zinc ions.  Nickel and cobalt ions inhibited bind-
ing of p53 to scDNA and to p53CON in linear DNA fragments less efficiently than zinc.
Compared to the intrinsic zinc strongly bound to Cys 176, Cys 238, Cys 242 and His 179 in
the p53 core domain, binding of additional Zn2+ to p53 was much weaker as shown by an easy
removal of the latter ions by low concentrations of EDTA. Oxidation of the protein with
diamide resulted in a decrease of the number of the retarded bands. Under the same conditions,
no binding of oxidized p53 to p53CON in a linear DNA fragment was observed. In agreement
with the literature oxidation of f.l. p53 with diamide was irreversible and was not reverted by
an excess of DTT. We showed that in the presence of 0.1 mM zinc ions, oxidation of p53
became reversible. Other divalent cations tested (cadmium, cobalt, nickel) exhibited no such
effect. We suggested that the irreversibility of p53 oxidation was due, at least in part, to the
removal of intrinsic zinc from its position in the DNA binding domain (after oxidation of the
three cysteines to which the zinc ion is coordinated in the reduced protein) accompanied by a
change in the p53 conformation. Binding of C-terminal anti-p53 antibody also protected bac-
terially expressed protein against irreversible loss of activity due to diamide oxidation.
Binding the human p53 core domain (segment 94-312) to scDNA greatly differed from that
observed with the full-length p53. The core domain did not posses the ability to bind strongly
to many sites in scDNA regardless of the presence or absence of p53CON suggesting involve-
ment of some other domain (probably C-terminal) in binding of the full-length p53 to scDNA.
Supershift experiments using antibodies against p53 N- or C-terminus suggested that in oxi-
dized p53, scDNA binding through the C-terminus gained importance.
Introduction
Protein p53 was discovered twenty years ago as a 53-kDa protein overexpressed in
cells transformed with SV40 virus (reviewed in (1); (2-4)). The protein tightly
bound to SV40 large T - antigen and was originally considered to be product of an
oncogene. However, later extensive studies of this molecule lead to conclusion that
normal biological role of p53 is to act as a tumor suppressor (reviewed in (5-12)).
Protein p53 is a stress-inducible transcription effector that activates expression of
genes involved in cell cycle arrest (p21/Waf1/Cip1), apoptosis (Bax) or DNA repair
(GADD45). One of the p53-inducible genes is also Mdm2, a negative regulator of
p53 involved in p53 nuclear export, degradation in proteosomes and, consequently,
maintaining of low p53 levels under normal conditions (13,14). Genotoxic stresses
such as DNA damage induce activation of p53 function by increasing the protein
level, its stabilization and activation by posttranslational modification (15-21).













1Institute of Biophysics, 
Academy of Sciences of 
the Czech Republic, 
Kralovopolska 135, 
612 65 Brno, Czech Republic 
2Masaryk Memorial Cancer Institute, 
656 53 Brno, Czech Republic; 













































prevents the cell to accumulate damaged DNA in further gener-
ations: the p53 pathway either arrests cell cycle in G1 or G2
phases (10,22), allowing the repair machinery to fix DNA dam-
age prior to replication or mitosis, or triggers apoptosis (23,24).
Mutations in the p53 gene that prevent normal function of the
p53 protein frequently result in genomic instability and malig-
nant transformation of the cells (12,25).
A crucial feature of p53 protein is its ability to bind DNA (19,
26-33). The protein consists of four structure-functional
domains two of which possess DNA-binding properties (Figure
1) (19,32,34). The core domain (amino acids 102-292 in human
protein) contains a DNA binding site that recognizes p53 con-
sensus sequence (p53CON) consisting of two copies of a
decanucleotide 5¢ -PuPuPuC(A/T)(T/A)GPyPyPy-3¢ separated
by 0-13 base pairs (35). X-ray crystallography identified a struc-
ture of two large loops held together by a tetrahedrally coordi-
nated zinc ion and a loop-sheet-helix motif representing the
DNA-binding surface of the p53 core (26). The same domain
was shown to interact also non-specifically with internal seg-
ments of long single- and double-stranded DNA molecules (31).
Another DNA-binding site of p53 is located in the carboxy-ter-
minal domain, in a basic region close to the extreme C-terminus.
This site binds non-sequence-specifically to single-stranded
DNA ends, and to mismatched or damaged DNA (36-40). This
C-terminal DNA binding site coincides with region that nega-
tively regulates DNA binding by the core domain in non-acti-
vated (latent) p53 (38). It was observed that  small nucleic acid
molecules activates p53 core domain through blocking of the
inhibition function of the C-terminus, and that the two DNA-
binding activities of p53 interfere reciprocally (31,37). It has
been proposed that recognition of damaged DNA by the p53 C-
terminus may trigger p53 activation.
Preferential Binding of Full Length Wild Type p53 to
Supercoiled DNA
Until recently,  the relation between DNA superhelicity and p53
DNA binding was not considered. We have found that human
wild type p53 strongly binds to negatively supercoiled (sc) plas-
mid DNA, regardless of the presence or absence of p53CON
(41-43). Depending on the protein/DNA ratio, complexes of p53
with scDNA produced a ladder of bands in agarose gel (Figure
2). After immunoblotting of the electrophoresed p53-DNA com-
plexes, ladder of p53 bands was obtained identical to the retard-
ed DNA bands on ethidium-stained gel (42,43) (Figure 2).
Recently, several groups have addressed the questions of the
influence of the p53 sequence-specific DNA binding on DNA
bending and twisting (44,45), and of the interaction of p53 with
non-B DNA structures that can be stabilized  by negative DNA
superhelicity (46-48). 
Modulation of p53 Binding to scDNA and to p53CON by Metal
Ions
We have shown that physiological concentrations of zinc ions
efficiently inhibit binding of f.l. p53 to scDNA (42). 5 m M Zn2+
partially inhibited binding to scDNA while 20 m M exhibited full
inhibition. This inhibition was cancelled by relatively low con-
centrations of EDTA or DTT suggesting that binding of addition-
al Zn2+ ions to p53 is substantially weaker than that of the intrin-
sic zinc in the core domain. Sequence-specific DNA binding was
influenced by zinc ions in a similar manner (42). The latter results
are at variance with the results of Coffer and Knowles (Coffer &
Knowles, 1994) that 100 m M Zn2+ has no effect on p53 binding
to p53CON in a 30-mer oligonucleotide. Although the reason for
this discrepancy is not completely clear, it cannot be excluded
that the presence of EDTA (and/or DTT) might have influenced
the results reported by Coffer and Knowles. 
Inhibition of p53 binding to DNA by zinc ions was discussed in
terms of the interaction of zinc ions with different sites in the p53
molecule (other than the site formed by Cys 176, Cys 238, Cys
242 and His 179), switching the p53 conformation to an inactive
(PAb1620-negative) immunological phenotype (49) and possibly
modifying the p53 DNA binding surface. The findings that level
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Figure 1: Scheme of structure-functional domains of p53 protein. DNA-binding
sites are located in the protein core and in the basic C-terminal domain.
Figure 2: Schematic representation of scDNA ethidium staining in agarose gel
and DO-1 immunoblot of p53. Sc, supercoiled DNA of (lanes 1,2,4) pBluescript
SK(-) (without p53 consensus sequence, p53CON) or (lane 3) pPGM1 (with
p53CON).  Lane 1, mobility of  free sc DNA in  agarose gel. Complexes of f.l.
p53 with scDNAs yield a ladder of bands, regardless of the presence or absence









































of zinc may play a role in signalling in vivo (50,51) and the role
of zinc ions in stabilization of p53 under oxidative conditions
(see above) suggest that modulation of p53 activity by zinc can
be considered as a physiologically relevant mechanism. Cobalt,
nickel and iron ions also inhibited p53 binding to scDNA and to
p53CON but at least an order of magnitude higher concentrations
(far above physiological levels, Table I) of these metals were
required to obtain the same effect as with zinc (42).
Redox Modulation of p53 Binding to Supercoiled DNA and to
p53CON in a Linear DNA Fragment
p53 core domain contains ten cysteine residues, including three
cysteines (amino acids 176, 238 and 242) coordinating zinc
atom (together with histidine 179) stabilizing proper conforma-
tion of p53 DNA binding site (26,52). Thiol groups can readily
be oxidized by variety of agents, including oxygen, hydroxyl
radicals, or specific agents such as diamide (azodicarboxylic
acid bis[dimethylamide]). Several groups (20,40,52-57) have
studied redox regulation of p53 binding to DNA.  It was estab-
lished that the p53 cysteines must be in a reduced state for
sequence-specific DNA binding (20,40,53). Loss of p53 binding
activity due to oxidation was accompanied by a conformational
change of the core domain from “wild type” (PAb1620+) to
“mutant” (PAb1620-)  immunological phenotype (53). 
We have found that binding of f.l. p53 to scDNA was influenced
by the protein redox state (43), and was partially decreased upon
oxidation of the protein with diamide (43) or  with 1 mM hydro-
gen peroxide (Figure 3). The decreased ability of oxidized p53
to bind scDNA was manifested by a decrease in the number of
retarded bands on the gel and on the immunoblot (43) (Figures
3,  5). On the contrary, binding of p53 to p53CON was fully lost
under the same conditions (Figure 4). Oxidized protein was,
however, able to bind linear DNA non-specifically, as manifest-
ed by an increased signal on the blot corresponding to p53 com-
plex with the 2.5 kb fragment of the pPGM1 plasmid (Figure 4,
lane 3). Parks et al. (40) concluded that the redox state of p53
does not regulate non-specific binding of the protein to 49-mer
double-stranded and mismatched DNAs. This conclusion is in
accordance with the expected preferential role of the C-terminal
domain (lacking redox-active cysteine residues) in p53 binding
to short  non-specific DNA molecules (31,37). Although the
amounts of labelled DNA bound by reduced and oxidized p53 in
the Parks’ experiments appear to be equal (40), the different
mobility shifts observed in the two cases suggest that the num-
ber of bound p53 molecules per DNA molecule may be influ-
enced by protein oxidation. Interestingly, an increase of binding
of p53 to the ds 49-mer can be observed in the results of Parks
et al. (40) when (probably supercoiled) Bluescript DNA was
used as a competitor. This observation is in agreement with our
results revealing decreased p53 binding to supercoiled DNA
upon protein oxidation (43). 
Irreversibility of p53 Oxidation by Diamide and Protection by
Zinc Ions
Redox modulation has been taken into account as a possible
mechanism of p53 regulation in vivo. Such a model requires
reversible interconversion between reduced (active) and oxidized
(inactive) state of the protein (20,40,53,55). Oxidation of f.l. bac-
ulovirus-expressed p53 by diamide resulted in an irreversible
loss of DNA binding activity that could not be reverted by addi-
tion of an excess of DTT (Figure 4). On the other hand, p53 oxi-
dized by ambient oxygen (e.g. when the protein was purified in
the absence of DTT, (40,53)) was easily reactivated by addition
of DTT. We observed similar behaviour with f.l. p53 oxidized
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Table I
Effects of metal ions on binding of p53 to DNA.
Minimal concentrations (m M) of metal ions required for partial or full
inhibition of the f.l. wild type p53 binding to scDNA and p53CON in
DNA fragments. Inhibition was tested at p53/DNA=10, in absence of
EDTA and concentration of DTT <100 m M.
scDNA p53CON in DNA fragment
ion partial full partial full
Zn 2+ 5 20 5 20
Ni2+ 100 300 50 100
Co2+ 300 800 100 300
Figure 3: Effects of oxidation of f.l. wild type p53 with diamide and with hydro-
gen peroxide followed by reduction with DTT on its binding to sc Bluescript
DNA. Protein p53 was incubated in different combinations with 1 mM diamide
(lanes 3-5) or 1 mM H2O2 (lanes 6-8) for 15 min followed by 4 mM DTT for 15
min in 50 mM KCl, 5 mM Tris-HCl (pH 7.8) at 0°C. Next, EDTA (final concen-
tration 1 mM) and 200 ng of scDNA were added. After 30 min incubation at 0°C,
the samples were loaded on 1 % agarose gel and electrophoresed. Order of incu-
bations with the reagents: lane 2, DTT - none; lane 3, DTT - diamide; lane 4, none
- diamide; lane 5, diamide - DTT; lane 6, DTT - H2O2; lane 7, none - H2O2; lane
8, H2O2 - DTT; lane 1, control DNA. Table below the panel indicates order of addi-
tion of the reagents: D, DTT; O, oxidant; p53/DNA = 5. Protein oxidized with
hydrogen peroxide yielded only retarded band 1 in agarose gel, displaying the
same behavior as diamide-oxidized p53 (lanes 7 and 4, respectively). After addi-
tion of an excess of DTT, however, p53 binding to scDNA significantly increased,
yielding more intense band 1 and weaker bands 2 and 3 (lane 8), suggesting par-
tial reversibility of p53 oxidation with H2O2. No distinct retarded bands except








































with 1 mM hydrogen peroxide (Figure 3). We assumed that this
reversibility might be due to partial oxidation of p53 which does
not result in the removal of the intrinsic  zinc ion from its posi-
tion in the 53 core domain. In agreement with this assumption
we have found that zinc ions at concentrations of 20-200 m M
protect diamide-oxidized baculovirus-expressed p53 against
irreversible inactivation (43) (Figure 4). This protection was
observed only when zinc was present in the medium during oxi-
dation (zinc displayed no protective effect on already oxidized
protein). Other divalent transition metals (cadmium, cobalt,
nickel) at 100 m M concentration did not protect p53; instead,
they promoted deeper structural changes in the oxidized protein,
resulting in loss of reactivity towards N-terminal domain-bind-
ing antibodies DO-1, DO-13 and DO-14 (43). We suggest that
irreversibility of diamide oxidative inactivation of f.l. p53 is, at
least partially due to release of the intrinsic zinc ion from its
binding site in p53 core domain, accompanied by a conforma-
tional change. These changes result in loss of p53 binding activ-
ity. Abundant zinc ions in the solution can be expected to act
against zinc removal (43). Rainwater et al. (52) observed that
removal of trace amounts of external zinc from the p53 solution
resulted in an increased sensitivity of the protein towards air oxi-
dation, as manifested in loss of its DNA binding activity.
Removal of the p53 intrinsic zinc by o-phenanthroline was asso-
ciated with oxidation of the thiol groups in the protein (53,58).
Recently we have observed that diamide oxidation (in the
absence of zinc) of bacterially expressed p53 activated by anti-
bodies Bp53-30 (Figure 4) and Bp53-10 (antibodies similar to
PAb421 (59) recognizing epitopes in the p53 C-terminus) result-
ed in reversible loss of sequence-specific binding. Furthermore,
binding of isolated p53 core 94-312 to p53CON, to scDNA and
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Figure 4: Comparison of the reversibility of redox modulation of sequence-spe-
cific binding of p53 (lanes 1-5) expressed in insect cells and (lanes 6-8) E. coli-
expressed p53 activated by antibody Bp53-30. Protein p53  was oxidized by 1
mM diamide (lanes 4-5, 8) followed by reduction by 2 mM DTT; (lane 5), oxi-
dation of p53 in presence of 100 m M Zn2+; (lane 6-7), monoclonal antibody
Bp53-30 was added to p53 prior to oxidation; (lanes 2, 6), reduced p53 incubat-
ed with 2 mM DTT; (lane 1), control DNA (pPGM1 cleaved with Pvu II). R;
band of sequence-specific complex of p53 with the 474 bp fragment; RS, band
R supershifted by the antibody; N, band due to non-specific p53-DNA binding;
p53-Ab, spot a complex of p53 with Bp53-30 not containing DNA.  (A), ethidi-
um-stained agarose gel; (B), DO-1 immunoblot. Table below the panels indicates
order of addition of the reagents (as in Figure 3); Z, zinc added together with
diamide. For other details see Figure 3. Antibody-activated p53 expressed in E.
coli was reversibly modulated by diamide oxidation followed by DTT reduction
(lanes 7,8). On the contrary, baculovirus-expressed p53 (not treated by the anti-
body) was irreversibly inactivated by the same oxidation procedure (lane 4).
Partial reversibility was attained when 100 m M zinc was present in the solution
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Figure 5: Supershifting of scDNA complexes with reduced or oxidized p53 by
monoclonal antibodies DO-1 (recognizing epitope in the p53 N-terminal
domain) and Bp53-10 (C-terminal). Protein p53 was preincubated with (lanes 2-
4), 2 mM DTT; (lanes 5 - 7), 1 mM diamide; (lanes 8 - 10), 1 mM diamide fol-
lowed by 2 mM DTT as in Figure 3. Then, 200 ng of sc Bluescript DNA was
added together with 100 ng of affinity-purified antibodies DO-1 (lanes 3, 6 and
9) or Bp53-30 (lanes 4, 7 and 10); (lanes 2, 5 and 8), no antibody; (lane 1), con-
trol DNA. (A), ethidium stained gel; (B), schematic superimposition of gel and
blot: empty rectangles, free DNA; filled rectangles, DNA-p53 complexes; 1S,
2S, 1S¢ , 2S¢ , supershifted bands 1, 2. For other details, see Figure 3. Monoclonal
antibody DO-1 (mapping p53 amino acids 20-25 in p53 N-terminus) supershift-
ed scDNA complexes with both reduced and oxidized p53 (lanes 3, 6) suggest-
ing that binding of this antibody to p53 did not prevent scDNA binding. On the
contrary,  antibody Bp53-10 (mapping amino acids 371-380 in the p53 C-termi-
nus) supershifted only scDNA complexes with reduced p53 (lane 4) showing no
supershift with oxidized p53 (lane 7). Addition of an excess of DTT was without
significant effect  (lanes 8-10), confirming irreversibility of the changes in p53
molecules due to diamide oxidation. 
Figure 6: Schematic representation of different modes of interactions of f.l. wild
type p53 with DNA.  Sequence-specific binding of p53 to its response elements
in DNA fragments is maintained by the p53 core domain. The same p53 domain
binds also to internal segments of long molecules of double- as well as single-
stranded DNA. C-terminal DNA-binding site of p53 interacts with single-strand-
ed ends of DNA molecules and with mismatched or otherwise damaged DNA.
In binding of p53 to supercoiled DNA both the core and the C-terminal p53








































to linear non-specific DNA was (at least partially) reversibly
modulated in vitro by oxidation with diamide and reduction
with DTT (M. Fojta, M. Brazdova,  T. Jovin, V. Subramaniam
and E. Palecek, unpublished results). Presence of 1 mM EDTA
resulted in loss of reversibility of the process (but did not influ-
ence DNA binding of reduced core domain in the presence of 1-
5 mM DTT) supporting the idea of zinc release due to oxidation.
Analogous results were previously reported by Hupp et al. (29)
who observed reversible modulation of sequence-specific DNA
binding of PAb421-activated or C-terminally truncated p53 upon
treatments with diamide and DTT. Interestingly, Hansen et al.
(60) observed that deletion of 30 amino acids from the p53 C-
terminus significantly enhanced thermostability of p53, suggest-
ing that the C-terminus contributes to instability of p53 core. 
Reversible Redox Modulation of p53 in vivo. The possibility of
reversible redox modulation of p53 DNA binding activity in vivo
was earlier considered by other authors (20,40,52-57). Oxidants
such as oxygen, hydrogen peroxide or radicals derived from
these species may occur in vivo and effect the p53 redox state.
Moreover, in vivo p53 is expected to interact with variety of pro-
teins. Some of them act as p53 regulators switching off the
inhibiting and destabilizing effect of the C-terminus (60) (“acti-
vating” antibodies such as PAb421 or Bp53-10 probably mimic
these natural effectors). These effectors may modulate or protect
p53 in response to different situations, including oxidative
stress, temperature shock, etc. For example, redox-repair protein
Ref-1 related to cellular response on oxidative stress was shown
to activate p53 by redox-dependent and redox-independent
mechanisms (20,55). Molecular chaperones such as DnaK or
Hsp70 (proteins protecting or restoring proper tertiary folding of
their specific target molecules), also activated p53 sequence-
specific DNA binding. These chaperones interact with the p53
core and dramatically enhance stability of p53 (60,61). In con-
text of the protective effect of zinc ions, it may be noted that zinc
metallothioneins have been shown to act (in redox-dependent
manner) as active zinc donors for other zinc metalloproteins
(62,63). Such mechanisms might be involved in  fine regulation
of p53 activity in vivo.
Involvement of p53 Domains in Binding to scDNA
We have shown that f.l. p53 binds preferentially to scDNA
(41,64). The affinity of this binding is comparable to the
sequence-specific binding to p53CON in linear DNA fragments
and substantially higher than that of nonspecific binding to
dsDNA. In addition to the known sequence-specific and non-
specific binding we may thus consider a new  p53 DNA binding
mode which might be tentatively called supercoiled-specific
(SCS) DNA binding. Strong SCS binding is observed with f.l.
p53 but not with its isolated core 94-312 (64). These findings in
combination with the observed effects of metal ions (42) and
p53 redox states (43) (Figures 3-5) allow us to make some ten-
tative conclusions about the involvement of the p53 domains in
SCS binding of f.l. p53 to DNA.
It was shown that two domains of p53 are involved in DNA
binding:  p53 core domain and C-terminus (19,34,37). We sug-
gested that both these p53 domains might be involved in binding
of reduced p53 to scDNA. Oxidized p53 is inactivated for the
DNA sequence-specific binding  (due to oxidation of cysteine
residues in the core domain) while the non-specific binding by
the C-terminus (not containing any cysteine) remains uninflu-
enced (40) (Figure 6). Binding to scDNA is significantly influ-
enced but not abolished by the p53 oxidation (43) (Figures 3, 5).
These results suggest that in p53 binding to scDNA both the core
and the C-terminal domains may be involved.
Quite recently we observed that oxidized isolated core 94-312
does not bind to scDNA (M. Fojta, M. Brazdova, V.
Subbramaniam, T. Jovin and E. Palecek, unpublished) strongly
supporting the idea that the remaining scDNA binding activity of
oxidized f.l. p53 is localized outside the core domain. We have
shown that p53-DNA complexes can be supershifted by anti-p53
monoclonal antibodies in agarose gels (65). Antibody Bp53-10
(59) mapping amino acids 371-380 in the p53 C-terminus super-
shifted complexes of reduced f.l. p53 with scDNA. On the other
hand, the same antibody inhibited binding of oxidized p53 to
scDNA (Figure 5) suggesting that the C-terminus is critical for
the residual binding of the oxidized f.l. p53 to scDNA. In con-
trast to the C-terminus binding Bp53-10, the DO-1 antibody,
binding to the N-terminal domain, showed the ability to super-
shift the p53-scDNA complexes regardless of the p53 redox
state. These observations suggest that the core domain is
involved in binding of f.l. p53 to scDNA and that the C-terminal
domain contributes to this binding. In the oxidized protein, bind-
ing by the C-terminal domain gains importance.
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